Department of Surgery (Neurosurgery, Neurobiology), McMaster University, Health Sciences Centre, 4E15, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada,
Purinergic Signal. 2008 Mar;4(1):61-71. doi: 10.1007/s11302-007-9093-8. Epub 2008 Jan 8.
Axonal demyelination is a consistent pathological sequel to chronic brain and spinal cord injuries and disorders that slows or disrupts impulse conduction, causing further functional loss. Since oligodendroglial progenitors are present in the demyelinated areas, failure of remyelination may be due to lack of sufficient proliferation and differentiation of oligodendroglial progenitors. Guanosine stimulates proliferation and differentiation of many types of cells in vitro and exerts neuroprotective effects in the central nervous system (CNS). Five weeks after chronic traumatic spinal cord injury (SCI), when there is no ongoing recovery of function, intraperitoneal administration of guanosine daily for 2 weeks enhanced functional improvement correlated with the increase in myelination in the injured cord. Emphasis was placed on analysis of oligodendrocytes and NG2-positive (NG2+) cells, an endogenous cell population that may be involved in oligodendrocyte replacement. There was an increase in cell proliferation (measured by bromodeoxyuridine staining) that was attributable to an intensification in progenitor cells (NG2+ cells) associated with an increase in mature oligodendrocytes (determined by Rip+ staining). The numbers of astroglia increased at all test times after administration of guanosine whereas microglia only increased in the later stages (14 days). Injected guanosine and its breakdown product guanine accumulated in the spinal cords; there was more guanine than guanosine detected. We conclude that functional improvement and remyelination after systemic administration of guanosine is due to the effect of guanosine/guanine on the proliferation of adult progenitor cells and their maturation into myelin-forming cells. This raises the possibility that administration of guanosine may be useful in the treatment of spinal cord injury or demyelinating diseases such as multiple sclerosis where quiescent oligodendroglial progenitors exist in demyelinated plaques.
轴突脱髓鞘是慢性脑和脊髓损伤及疾病的一种常见病理后果,它会减缓或中断冲动传导,导致进一步的功能丧失。由于少突胶质前体细胞存在于脱髓鞘区域,髓鞘再生的失败可能是由于少突胶质前体细胞增殖和分化不足所致。鸟苷在体外能刺激多种细胞的增殖和分化,并在中枢神经系统(CNS)中发挥神经保护作用。在慢性创伤性脊髓损伤(SCI)后 5 周,当功能没有持续恢复时,腹腔内每天给予鸟苷治疗 2 周,可增强功能改善,与损伤脊髓中的髓鞘形成增加相关。重点分析了少突胶质细胞和 NG2 阳性(NG2+)细胞,这是一种内源性细胞群体,可能参与少突胶质细胞的替代。细胞增殖(通过溴脱氧尿苷染色测量)增加,这归因于与成熟少突胶质细胞(通过 Rip+染色确定)增加相关的祖细胞(NG2+细胞)的强化。在给予鸟苷后的所有测试时间点,星形胶质细胞的数量都增加,而小胶质细胞仅在后期(14 天)增加。注射的鸟苷及其分解产物鸟嘌呤积聚在脊髓中;检测到的鸟嘌呤多于鸟苷。我们的结论是,全身给予鸟苷后功能改善和髓鞘再生是由于鸟苷/鸟嘌呤对成年祖细胞增殖及其向髓鞘形成细胞成熟的影响。这提出了一种可能性,即给予鸟苷可能对治疗脊髓损伤或脱髓鞘疾病如多发性硬化症有用,因为在脱髓鞘斑块中存在静止的少突胶质前体细胞。